Loading clinical trials...
Loading clinical trials...
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alpha for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Due to Myelodysplastic Syndrome (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions
Conditions
Interventions
Luspatercept
Epoetin alfa
Locations
226
United States
Local Institution - 107
Berkeley, California, United States
Local Institution - 115
San Diego, California, United States
Local Institution - 101
Whittier, California, United States
Local Institution - 104
New Haven, Connecticut, United States
Local Institution - 136
Washington D.C., District of Columbia, United States
Local Institution - 119
Hudson, Florida, United States
Start Date
January 2, 2019
Primary Completion Date
March 31, 2023
Completion Date
September 28, 2027
Last Updated
November 20, 2024
NCT07270978
NCT05292664
NCT06499285
NCT04953910
NCT04953897
NCT05350748
Lead Sponsor
Celgene
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions